Amedeo Smart

Free Medical Literature Service

 

Amedeo

Stem Cell Research
  Free Subscription

Articles published in
Bone Marrow Transplant
    February 2026
  1. CEREZO-MARTIN JM, Yanez L, Colorado M, Salas MQ, et al
    Real-world experience of treosulfan in allogeneic stem cell transplantation in adult patients with myeloid malignancies. Spanish Group of SCT and Cell Therapy (GETH-TC).
    Bone Marrow Transplant. 2026 Feb 25. doi: 10.1038/s41409-026-02804.
    >> Share

    January 2026
  2. PAN Y, Zuo Y, Cui Q, Liu S, et al
    Treatment outcome and efficacy of desensitization strategies for immunized-PTR in hematological malignancies before hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2026 Jan 28. doi: 10.1038/s41409-025-02749.
    >> Share

  3. MASSOUD R, Klyuchnikov E, Heidenreich S, Manjarres MB, et al
    Impact of anti-T-lymphocyte globulin dosing on graft versus host disease in matched sibling peripheral blood stem cell transplantation.
    Bone Marrow Transplant. 2026 Jan 21. doi: 10.1038/s41409-025-02761.
    >> Share

  4. IBRAHIMOVA A, Bidgoli A, Ashraf A, Krogman A, et al
    Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults.
    Bone Marrow Transplant. 2026 Jan 21. doi: 10.1038/s41409-025-02795.
    >> Share

  5. WATANABE M, Ohtera S, Kanda J, Hiragi S, et al
    Correction: Real-world medical expenses of hematopoietic stem cell transplantation in Japan: a nationwide database study.
    Bone Marrow Transplant. 2026 Jan 7. doi: 10.1038/s41409-025-02781.
    >> Share

  6. MELE D, Malagola M, Zavaglio F, Grassia G, et al
    Human cytomegalovirus-specific T-cell responses and immune-guided strategies as predictors of clinically significant infection in hematopoietic stem cell transplant recipients after letermovir prophylaxis.
    Bone Marrow Transplant. 2026 Jan 7. doi: 10.1038/s41409-025-02788.
    >> Share

    December 2025
  7. SERPENTI F, Galli N, Cavallaro F, Barbullushi K, et al
    Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience.
    Bone Marrow Transplant. 2025 Dec 27. doi: 10.1038/s41409-025-02790.
    >> Share

  8. SHEIKH IN, Alqahtani S, Okeleji O, Brown BD, et al
    Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes.
    Bone Marrow Transplant. 2025 Dec 10. doi: 10.1038/s41409-025-02776.
    >> Share

  9. PASVOLSKY O, Marcoux C, Milton DR, Haider AA, et al
    Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma.
    Bone Marrow Transplant. 2025 Dec 5. doi: 10.1038/s41409-025-02771.
    >> Share

  10. FRANKE GN, Ussmann J, Backhaus D, Nicolay NH, et al
    The sequence of 12 Gy total body irradiation and cyclophosphamide does not impact outcomes in AML patients receiving myeloablative allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2025 Dec 2. doi: 10.1038/s41409-025-02755.
    >> Share

  11. BERTAINA A, Maffeis M, Lucchini G, Galimard JE, et al
    Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PD
    Bone Marrow Transplant. 2025 Dec 1. doi: 10.1038/s41409-025-02748.
    >> Share

    November 2025
  12. SUN Y, Zhu J, Chen J, Jiang E, et al
    Incidence and risk factors for graft failure after allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
    Bone Marrow Transplant. 2025 Nov 25. doi: 10.1038/s41409-025-02746.
    >> Share

  13. BARBULLUSHI K, Labopin M, Kroger N, Finke J, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.
    Bone Marrow Transplant. 2025 Nov 21. doi: 10.1038/s41409-025-02740.
    >> Share

  14. WATANABE M, Ohtera S, Kanda J, Hiragi S, et al
    Real-world medical expenses of hematopoietic stem cell transplantation in Japan: a nationwide database study.
    Bone Marrow Transplant. 2025 Nov 15. doi: 10.1038/s41409-025-02753.
    >> Share

  15. KURIYAMA K, Watanabe M, Okatani T, Ota S, et al
    Outcomes of hematopoietic stem cell transplantation for patients with monomorphic epitheliotropic intestinal T-cell lymphoma: retrospective study from the Adult Lymphoma Working Group of the Japan Society for Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Nov 15. doi: 10.1038/s41409-025-02752.
    >> Share

  16. CHOE H, DeFilipp Z
    Current therapeutics for sclerotic and fibrotic manifestations of chronic graft-versus-host disease.
    Bone Marrow Transplant. 2025 Nov 13. doi: 10.1038/s41409-025-02743.
    >> Share

  17. ROCHA V, Labopin M, Raiola AM, Devillier R, et al
    Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT.
    Bone Marrow Transplant. 2025 Nov 5. doi: 10.1038/s41409-025-02735.
    >> Share

    October 2025
  18. LAZANA I, Gkirkas K, Konstantellos I, Chatzidimitriou C, et al
    Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.
    Bone Marrow Transplant. 2025 Oct 23. doi: 10.1038/s41409-025-02736.
    >> Share

  19. GALAVERNA F, Styczynski J, Ljungman P
    Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients.
    Bone Marrow Transplant. 2025 Oct 22. doi: 10.1038/s41409-025-02739.
    >> Share

  20. JANSSEN MJM, de Witte MA, Daenen LGM, Verduyn Lunell F, et al
    Preserved measles immunity after allogeneic hematopoietic stem cell transplantation in a cohort of mainly alphabeta T-cell-depleted graft recipients.
    Bone Marrow Transplant. 2025 Oct 6. doi: 10.1038/s41409-025-02731.
    >> Share

  21. RAJU G, Walji M, Nemirovsky D, Devlin S, et al
    Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.
    Bone Marrow Transplant. 2025 Oct 4. doi: 10.1038/s41409-025-02721.
    >> Share

    September 2025
  22. GRECO R, Saccardi R, Ponzano M, Badoglio M, et al
    BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party.
    Bone Marrow Transplant. 2025 Sep 29. doi: 10.1038/s41409-025-02715.
    >> Share

  23. ECHECOPAR C, Bueno Sanchez D, Leon Triana O, Molina Angulo B, et al
    The use of mesenchymal stromal cells in steroid-refractory graft-versus-host disease after pediatric hematopoietic stem cell transplantation: a report of the Spanish group of stem cell transplantation (Geth).
    Bone Marrow Transplant. 2025 Sep 26. doi: 10.1038/s41409-025-02717.
    >> Share

  24. TSIRIGOTIS P, Lazana I
    Donor-derived malignancy after allogeneic stem cell transplantation: a rare but well recognized complication.
    Bone Marrow Transplant. 2025 Sep 26. doi: 10.1038/s41409-025-02725.
    >> Share

  25. MICHIELSEN LA, de Witte MA, Daenen LGM, Janssen A, et al
    Pure white cell aplasia following allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Sep 25. doi: 10.1038/s41409-025-02712.
    >> Share

  26. LEARDINI D, Roberto M, Roggiani S, Muratore E, et al
    Hematopoietic stem cell transplantation disrupts age-related gut microbiota signatures in pediatric and adult recipients.
    Bone Marrow Transplant. 2025 Sep 25. doi: 10.1038/s41409-025-02713.
    >> Share

  27. OTOUKESH S, Amanam I, Yang D, Samuels D, et al
    Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis.
    Bone Marrow Transplant. 2025 Sep 24. doi: 10.1038/s41409-025-02724.
    >> Share

  28. VIVEROS-LUGO MA, Cruz-Perez GE, Garcia-Velez D, Chavez-Martinez S, et al
    Predicting the response to hematopoietic stem cell transplantation in persons with multiple sclerosis: the significance of an early positive response.
    Bone Marrow Transplant. 2025 Sep 20. doi: 10.1038/s41409-025-02707.
    >> Share

  29. FUJII T, Sakurai M, Shimizu H, Izumi A, et al
    Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Sep 15. doi: 10.1038/s41409-025-02718.
    >> Share

  30. BARTHELEMY C, Jestin M, Brignier A, Parquet N, et al
    Early administration of selected CD34 peripheral blood stem cell following bone marrow transplantation to prevent graft rejection: experience in haploidentical transplant for sickle cell disease.
    Bone Marrow Transplant. 2025 Sep 12. doi: 10.1038/s41409-025-02685.
    >> Share

  31. WEBER D, Meedt E, Ghimire S, Hiergeist A, et al
    "The antibiotic paradox" in allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2025 Sep 4. doi: 10.1038/s41409-025-02706.
    >> Share

    August 2025
  32. FOKKEMA C, Appelman MK, Veldhoen N, Spelt A, et al
    Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab.
    Bone Marrow Transplant. 2025 Aug 30. doi: 10.1038/s41409-025-02681.
    >> Share

  33. DEL PAPA N, Labopin M, Badoglio M, Farge D, et al
    Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Aug 27. doi: 10.1038/s41409-025-02684.
    >> Share

  34. CESARO S, Verheggen I, Tridello G, Styczynski J, et al
    A survey on the practices and the management of hemorrhagic cystitis in patients who undergo allogeneic hematopoietic stem cell transplantation, on behalf of the Infectious Diseases Working Party of EBMT.
    Bone Marrow Transplant. 2025 Aug 26. doi: 10.1038/s41409-025-02703.
    >> Share

  35. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
    Bone Marrow Transplant. 2025 Aug 23. doi: 10.1038/s41409-025-02699.
    >> Share

  36. ALEXANDER T, Roldan E, Del Papa N, Farge D, et al
    Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.
    Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02695.
    >> Share

  37. PULANIC D, Peczynski C, Boreland W, Rautenberg C, et al
    Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party.
    Bone Marrow Transplant. 2025 Aug 19. doi: 10.1038/s41409-025-02697.
    >> Share

  38. CHEN H, Xu LP, Zhang XH, Wang Y, et al
    Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Bone Marrow Transplant. 2025 Aug 18. doi: 10.1038/s41409-025-02698.
    >> Share

  39. WILCKEN H, Kaier K, Meyer T, Waterhouse M, et al
    Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study.
    Bone Marrow Transplant. 2025 Aug 2. doi: 10.1038/s41409-025-02689.
    >> Share

    July 2025
  40. STEPANYANTS V, Li H, Cenin D, Edwards J, et al
    Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil.
    Bone Marrow Transplant. 2025 Jul 31. doi: 10.1038/s41409-025-02690.
    >> Share

  41. IACOBELLI S, Schonland S, Koster L, Blaise D, et al
    Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2025 Jul 30. doi: 10.1038/s41409-025-02675.
    >> Share

  42. BATTISTA ML, Facchin G, De Martino M, Chiusolo P, et al
    Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy.
    Bone Marrow Transplant. 2025 Jul 26. doi: 10.1038/s41409-025-02674.
    >> Share

  43. MORALES D, Loth G, Colturato VAR, Tavares RB, et al
    Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study.
    Bone Marrow Transplant. 2025 Jul 24. doi: 10.1038/s41409-025-02676.
    >> Share

  44. HATZAKIS A, Maybury BD, Chaganti S, Stevens A, et al
    Allogeneic haematopoietic stem cell transplantation in advanced cutaneous T-cell lymphomas offers curative potential.
    Bone Marrow Transplant. 2025 Jul 23. doi: 10.1038/s41409-025-02683.
    >> Share

  45. PENACK O, Bacigalupo A, Gavriilaki E, Greinix H, et al
    Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study.
    Bone Marrow Transplant. 2025 Jul 22. doi: 10.1038/s41409-025-02687.
    >> Share

  46. SIVARAJ D, Bacon W, Long GD, Rizzieri DA, et al
    Correction: High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Bone Marrow Transplant. 2025 Jul 21. doi: 10.1038/s41409-025-02663.
    >> Share

  47. SHAHZAD M, Mohsin A, Khamees I, Rehman AU, et al
    Impact of body mass index on outcomes following allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Jul 17. doi: 10.1038/s41409-025-02680.
    >> Share

  48. GUO LP, Hu LJ, Mo XD, Sun YQ, et al
    Characteristics and prognosis of central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with leukemia.
    Bone Marrow Transplant. 2025 Jul 17. doi: 10.1038/s41409-025-02673.
    >> Share

  49. RITTER J, Marco T, Angeletti M, Barnett D, et al
    Autologous hematopoietic stem cell transplantation in severe, refractory stiff person syndrome: a case series.
    Bone Marrow Transplant. 2025 Jul 16. doi: 10.1038/s41409-025-02686.
    >> Share

  50. SHI C, Zeng X, Ge J, Qiu Y, et al
    Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers.
    Bone Marrow Transplant. 2025 Jul 4. doi: 10.1038/s41409-025-02666.
    >> Share

  51. GIL-MANSO R, Hidalgo Calleja C, Puebla Tornero L, Cabero-Martinez A, et al
    Nabiximols oromucosal spray in patients with chronic graft-versus-host disease: effects on sclerodermatous features and refractory muscle cramps.
    Bone Marrow Transplant. 2025 Jul 1. doi: 10.1038/s41409-025-02665.
    >> Share

    June 2025
  52. BEKADJA MA, Niederwieser D, Kharfan-Dabaja MA, El Fakih R, et al
    Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Jun 30. doi: 10.1038/s41409-025-02664.
    >> Share

  53. JING Z, Zhao L, Mai Y, Sun P, et al
    Hematopoietic stem cell transplantation outcomes in pediatric acquired aplastic anemia with inherited bone marrow failure syndrome-associated genes.
    Bone Marrow Transplant. 2025 Jun 25. doi: 10.1038/s41409-025-02671.
    >> Share

  54. TURKIEWICZ D, Elmer E, Lenhoff S, Dykes J, et al
    Letermovir prophylaxis may increase the risk of graft-versus-host disease after haploidentical hematopoietic stem cell transplantation with alphabeta(+) T cell depleted grafts.
    Bone Marrow Transplant. 2025 Jun 10. doi: 10.1038/s41409-025-02642.
    >> Share

  55. SAYYED A, Novitzky-Basso I, Remberger M, Clarke S, et al
    Prolonged length of stay in high-risk patients undergoing allogeneic stem cell transplantation: a call to action for addressing healthcare challenges.
    Bone Marrow Transplant. 2025 Jun 3. doi: 10.1038/s41409-025-02627.
    >> Share

  56. CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al
    Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study.
    Bone Marrow Transplant. 2025 Jun 2. doi: 10.1038/s41409-025-02632.
    >> Share

  57. RUEDA-LARA M, Barrera I, Komanduri KV, Pereira D, et al
    Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse population.
    Bone Marrow Transplant. 2025 Jun 2. doi: 10.1038/s41409-025-02636.
    >> Share

    May 2025
  58. MENGHESHA L, Tahmaz V, Holtick U, Scheid C, et al
    The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease.
    Bone Marrow Transplant. 2025 May 30. doi: 10.1038/s41409-025-02628.
    >> Share

  59. NAGLER A, Ferhat AT, Kayser S, Eder M, et al
    Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the ALWP /EBMT.
    Bone Marrow Transplant. 2025 May 29. doi: 10.1038/s41409-025-02620.
    >> Share

  60. KUROSAWA S, Kojo K, Yamakawa R, Kato K, et al
    Improved non-relapse mortality in allogeneic hematopoietic stem cell transplantation: a long-standing multidisciplinary pursuit at a single center.
    Bone Marrow Transplant. 2025 May 20. doi: 10.1038/s41409-025-02625.
    >> Share

  61. BATTIPAGLIA G, Labopin M, Kulagin A, Versluis J, et al
    Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant cyclophosphamide results in lower incidence of extensive chronic graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell transplantation for acute mye
    Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02610.
    >> Share

  62. DAENEN LGM, van der Wagen LE, Bonneville EF, Lopez-Corral L, et al
    The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.
    Bone Marrow Transplant. 2025;60:708-714.
    >> Share

    April 2025
  63. IBRAHIMOVA A, Khoury R, Jodele S, Grimley M, et al
    Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Apr 29. doi: 10.1038/s41409-025-02601.
    >> Share

  64. PERMINOVA M, Shelikhova L, Klimentova M, Skvortsova Y, et al
    Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial.
    Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02566.
    >> Share

  65. TARANTINO S, Labopin M, Zeiser R, Stelljes M, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in active disease: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02596.
    >> Share

  66. OZTURK G, Yesilipek MA, Akcay A, Uygun V, et al
    Effect of genetic mutations on outcomes of stem cell transplantation in children with hemophagocytic lymphohistiocytosis.
    Bone Marrow Transplant. 2025 Apr 22. doi: 10.1038/s41409-025-02592.
    >> Share

  67. CHUMNUMSIRIWATH P, Vittayawacharin P, Ramos-Perez J, Jeyakumar D, et al
    Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT).
    Bone Marrow Transplant. 2025 Apr 22. doi: 10.1038/s41409-025-02595.
    >> Share

  68. NAIR V, Kathrotiya M, Shirure V, Bhise S, et al
    Feasibility and efficacy of partial replacement of post transplantation cyclophosphamide with bendamustine on day +4 for graft versus host disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2025 Apr 21. doi: 10.1038/s41409-025-02581.
    >> Share

  69. RAVAIOLI F, Colecchia A, Peccatori J, Pagliara D, et al
    Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicent
    Bone Marrow Transplant. 2025 Apr 19. doi: 10.1038/s41409-025-02570.
    >> Share

  70. BERGLAND BS, Remberger M, Tjonnfjord GE, Vo CD, et al
    Should a young matched unrelated donor be preferred over an older matched related donor in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome?
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02579.
    >> Share

  71. BAYOUMY M, Raffa EH, Alharbi AA, Abosoudah I, et al
    Outcomes of Hematopoietic Stem Cell Transplantation in children with Sickle Cell Disease: Does donor Sickle cell trait status matter?
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02572.
    >> Share

  72. GALEANO S, Bonfim C, Karduss A, Jaimovich G, et al
    Results of the Latin American Bone Marrow Transplantation Society (LABMT) activity survey 2019-2022: the impact of the COVID-19 pandemic and the increase in related haploidentical donors.
    Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02600.
    >> Share

  73. LETAILLEUR V, Jullien M, Garnier A, Peterlin P, et al
    Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Apr 16. doi: 10.1038/s41409-025-02589.
    >> Share

  74. LYSANDROU M, Kefala D, Vinnakota JM, Savvopoulos N, et al
    Regulatory T cell therapy for Graft-versus-Host Disease.
    Bone Marrow Transplant. 2025 Apr 16. doi: 10.1038/s41409-025-02553.
    >> Share

  75. VERBEEK AB, von Asmuth EGJ, van den Akker EB, Jansen-Hoogendijk AM, et al
    Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients.
    Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02583.
    >> Share

  76. BREHM N, Biavasco F, Clausen J, Jung J, et al
    Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.
    Bone Marrow Transplant. 2025 Apr 14. doi: 10.1038/s41409-025-02586.
    >> Share

  77. BERGENS MA, Lowder YP, Li Y, Johnson EJ, et al
    Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.
    Bone Marrow Transplant. 2025 Apr 12. doi: 10.1038/s41409-025-02587.
    >> Share

  78. GONZALEZ VICENT M, Pereto A, Zubicaray J, Molina B, et al
    Outcomes in allogeneic hematopoietic stem cell transplantation for Fanconi anemia.
    Bone Marrow Transplant. 2025 Apr 12. doi: 10.1038/s41409-025-02591.
    >> Share

  79. SENAPATI J, Garcia-Manero G, DiNardo CD, Deshmukh I, et al
    Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590.
    >> Share

  80. ORTI G, Dachy G, Graham CE, Peric Z, et al
    Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practi
    Bone Marrow Transplant. 2025 Apr 9. doi: 10.1038/s41409-025-02567.
    >> Share

  81. SUREDA A, Pavlovsky A, Haidar D, Kristo F, et al
    Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557.
    >> Share

  82. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study by the ATL working group of the Japanese Society for
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563.
    >> Share

  83. LOPEZ-CORRAL L, Blazquez-Goni C, Perez-Lopez E, Martin-Dominguez FM, et al
    GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.
    Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02562.
    >> Share

  84. LIU J, Mai Y, Jing Z, Zhao L, et al
    Protective factors, management and prognosis of mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia in children.
    Bone Marrow Transplant. 2025 Apr 6. doi: 10.1038/s41409-025-02577.
    >> Share

  85. BARANWAL A, Kassis R, Hassan K, Kutzke J, et al
    Outcomes of attenuated dose fludarabine and melphalan based conditioning regimen in patients undergoing allogeneic stem cell transplant: a propensity score-matched analysis.
    Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02565.
    >> Share

  86. PENA M, Martinez DF, Paviglianiti A, Balaguer A, et al
    Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC.
    Bone Marrow Transplant. 2025 Apr 2. doi: 10.1038/s41409-025-02559.
    >> Share

  87. CHEN W, Zhang Y, Guo J, Wu X, et al
    The pre-ASCT serum albumin and pre-ASCT dFLC are prognostic markers in renal light chain amyloidosis patients treated with autologous stem cell transplantation.
    Bone Marrow Transplant. 2025 Apr 1. doi: 10.1038/s41409-025-02575.
    >> Share

  88. MICHONNEAU D, Malard F, Le Grand S, Magro L, et al
    Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Apr 1. doi: 10.1038/s41409-025-02554.
    >> Share

    March 2025
  89. MINAKATA D, Fujiwara SI, Honda S, Tominaga R, et al
    Impact of daratumumab on the development of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.
    Bone Marrow Transplant. 2025 Mar 23. doi: 10.1038/s41409-025-02558.
    >> Share

  90. SANTORO N, Schmid C, de Witte M, Roeven MWH, et al
    Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT.
    Bone Marrow Transplant. 2025 Mar 23. doi: 10.1038/s41409-025-02555.
    >> Share

  91. PINANA JL, Mico-Cerda M, Gomez D, Perez A, et al
    Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment.
    Bone Marrow Transplant. 2025 Mar 22. doi: 10.1038/s41409-025-02549.
    >> Share

  92. STORCK TN, Morsink LM, Biswana A, Hazenberg CLE, et al
    Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients.
    Bone Marrow Transplant. 2025 Mar 19. doi: 10.1038/s41409-025-02552.
    >> Share

  93. KLEINSCHMIDT K, Penkivech G, Troeger A, Foell J, et al
    alphass T-cell depleted haploidentical stem cell transplantation for pediatric and young adult patients with transfusion-dependent thalassemia.
    Bone Marrow Transplant. 2025 Mar 18. doi: 10.1038/s41409-025-02546.
    >> Share

  94. GAVRIILAKI E, Evangelidis P, Kotsiou N, Sakellari I, et al
    Antifungal prescription and stewardship in hematology and hematopoietic stem cell transplantation units worldwide: an international survey of EHA-SWG Infections in Hematology.
    Bone Marrow Transplant. 2025 Mar 9. doi: 10.1038/s41409-025-02545.
    >> Share

  95. SCHULZ E, Pirsl F, McGraw K, Nousome D, et al
    Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease.
    Bone Marrow Transplant. 2025 Mar 8. doi: 10.1038/s41409-025-02537.
    >> Share

  96. CALVO C, Mornet C, Storey C, Halfon-Domenech C, et al
    Adult height and growth hormone therapy in childhood acute lymphoblastic leukemia survivors treated with total body irradiation and hematopoietic stem cell transplantation before puberty.
    Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02532.
    >> Share

  97. ZHEN S, Liu L, Zhang X, Wang J, et al
    Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell transplantation in the letermovir era for cytomegaloviru
    Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02542.
    >> Share

    February 2025
  98. KOLLER PB, Othman T, Yang D, Mokhtari S, et al
    Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect.
    Bone Marrow Transplant. 2025 Feb 27. doi: 10.1038/s41409-025-02523.
    >> Share

  99. VIDAL A, Bora C, Jarisch A, Pape J, et al
    Impact of haematopoietic stem cell transplantation for benign and malignant haematologic and non-haematologic disorders on fertility: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2025 Feb 26. doi: 10.1038/s41409-025-02520.
    >> Share

  100. MUCHTAR E, Dispenzieri A, Sanchorawala V, Hassan H, et al
    A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis.
    Bone Marrow Transplant. 2025 Feb 24. doi: 10.1038/s41409-025-02535.
    >> Share

  101. RANDI BA, Higashino HR, Ponzio V, Abdala E, et al
    COVID-19 prior to hematopoietic stem cell transplantation increases the risk of acute graft-versus-host disease but does not affect overall mortality.
    Bone Marrow Transplant. 2025 Feb 21. doi: 10.1038/s41409-025-02536.
    >> Share

  102. LIN MH, Huang XJ, Xu LP, Wang Y, et al
    The haematopoietic cell transplantation comorbidity index predicts clinical outcomes for severe aplastic anaemia patients after haploidentical haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02513.
    >> Share

  103. ZHOU J, Wang F, Yang S, Zhang Y, et al
    Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528.
    >> Share

  104. SANZ J, Labopin M, Versluis J, Blaise D, et al
    Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT.
    Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02527.
    >> Share

  105. MODI B, Ngo D, Chen J, Yang D, et al
    Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience.
    Bone Marrow Transplant. 2025 Feb 4. doi: 10.1038/s41409-024-02498.
    >> Share

  106. TAN JY, Koh LP, Woon YK, Heng KK, et al
    A formula using day 4 parameters to predict next-day peripheral blood stem cell yield in healthy haematopoietic stem cell donors.
    Bone Marrow Transplant. 2025 Feb 3. doi: 10.1038/s41409-024-02503.
    >> Share

    January 2025
  107. RODRIGUES AM, Fernandes JF, Gregianin L, Nichele S, et al
    Hematopoietic stem cell transplantation in inborn errors of metabolism-a retrospective analysis on behalf of the pediatric disease working party from the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2025 Jan 26. doi: 10.1038/s41409-025-02512.
    >> Share

  108. SINDONI MM, Limido F, Toso A, Lucchini G, et al
    aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection.
    Bone Marrow Transplant. 2025 Jan 9. doi: 10.1038/s41409-025-02509.
    >> Share

  109. WANG Q, Liu M, Zhang S, Gao L, et al
    Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2025 Jan 7. doi: 10.1038/s41409-024-02502.
    >> Share

  110. HUANG XB, Yang X, Li CL, Zhang R, et al
    Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.
    Bone Marrow Transplant. 2025 Jan 6. doi: 10.1038/s41409-024-02470.
    >> Share

    December 2024
  111. YU F, Niu J, Yang J, Hou J, et al
    Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai.
    Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500.
    >> Share

  112. BRIJS J, Peczynski C, Boreland W, Cuoghi A, et al
    Immune checkpoint inhibitors therapy for solid organ malignancies after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT Transplant Complications Working Party.
    Bone Marrow Transplant. 2024 Dec 13. doi: 10.1038/s41409-024-02497.
    >> Share

  113. FALCO-ROGET A, Raiola AM, Balletto E, Varaldo R, et al
    Pre-engraftment bloodstream infection after allogeneic haematopoietic cell transplant: 18-year trends in aetiology, resistance and mortality.
    Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02494.
    >> Share

  114. ESCAMILLA-GOMEZ V, Garcia Gutierrez V, Alcalde-Mellado P, Astibia-Mahillo B, et al
    Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
    Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02483.
    >> Share

  115. MURATORE E, Gambuti G, Leardini D, Baccelli F, et al
    The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02489.
    >> Share

  116. GRIEB N, Oeser A, Ferle M, Hanke F, et al
    Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Bone Marrow Transplant. 2024 Dec 5. doi: 10.1038/s41409-024-02490.
    >> Share

  117. SUN J, Zhang YC, Wei J, Xu YJ, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study.
    Bone Marrow Transplant. 2024 Dec 2. doi: 10.1038/s41409-024-02485.
    >> Share

    November 2024
  118. GIAMMARCO S, Maggi R, Di Marino L, Chiusolo P, et al
    The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience.
    Bone Marrow Transplant. 2024 Nov 21. doi: 10.1038/s41409-024-02475.
    >> Share

  119. GIAMMARCO S, Limongiello MA, Di Marino L, Metafuni E, et al
    The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA.
    Bone Marrow Transplant. 2024 Nov 20. doi: 10.1038/s41409-024-02479.
    >> Share

  120. MAINGUY A, Soussain C, Touitou V, Bennedjai A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
    Bone Marrow Transplant. 2024 Nov 19. doi: 10.1038/s41409-024-02477.
    >> Share

  121. CHIN MM, Tamaresis JS, Johnston LJ, Lowsky R, et al
    Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
    Bone Marrow Transplant. 2024 Nov 18. doi: 10.1038/s41409-024-02476.
    >> Share

  122. MOLINOS-QUINTANA A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, et al
    Successful allogeneic CD34(+) hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
    Bone Marrow Transplant. 2024 Nov 17. doi: 10.1038/s41409-024-02473.
    >> Share

  123. LI SQ, Yu CZ, Xu LP, Wang Y, et al
    Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.
    Bone Marrow Transplant. 2024 Nov 16. doi: 10.1038/s41409-024-02466.
    >> Share

  124. XU LP, Lu PH, Wu DP, Huang H, et al
    Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02438.
    >> Share

  125. MAMEZ AC, Pradier A, Morin S, Giannotti F, et al
    Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02458.
    >> Share

  126. JEKER B, Thalmann L, Bacher U, Nilius H, et al
    Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial.
    Bone Marrow Transplant. 2024 Nov 15. doi: 10.1038/s41409-024-02468.
    >> Share

  127. SEVER M, Drozd-Sokolowska J, Gras L, Koster L, et al
    Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Nov 12. doi: 10.1038/s41409-024-02460.
    >> Share

  128. LI L, Chen Y, Chen T, Xu Y, et al
    Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China.
    Bone Marrow Transplant. 2024 Nov 8. doi: 10.1038/s41409-024-02454.
    >> Share

  129. ALEXANDER T, Badoglio M, Labopin M, Daikeler T, et al
    Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP).
    Bone Marrow Transplant. 2024 Nov 7. doi: 10.1038/s41409-024-02461.
    >> Share

  130. MAHMOUDJAFARI Z, Bhatt V, Galvin J, Xue Z, et al
    Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.
    Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02445.
    >> Share

    October 2024
  131. ZHANG ZL, Tong J, Lu RN, Scutt AM, et al
    Retraction Note: Therapeutic potential of non-adherent BM-derived mesenchymal stem cells in tissue regeneration.
    Bone Marrow Transplant. 2024 Oct 24. doi: 10.1038/s41409-024-02441.
    >> Share

  132. JUNEJA M, Prabahran A, Rawicki M, Chee LCY, et al
    The economic cost of care in poor graft function following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Oct 24. doi: 10.1038/s41409-024-02452.
    >> Share

  133. WANG Y, Gao WH, Wang LN, Wang L, et al
    Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors.
    Bone Marrow Transplant. 2024 Oct 22. doi: 10.1038/s41409-024-02436.
    >> Share

  134. AVIGAN ZM, Arinsburg S, Pan D, Mark T, et al
    Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Bone Marrow Transplant. 2024 Oct 18. doi: 10.1038/s41409-024-02442.
    >> Share

  135. ALSULIMAN T, Psimaras D, Stocker N, Sestili S, et al
    Autologous hematopoietic stem cell transplantation in a patient with multi-refractory stiff person syndrome.
    Bone Marrow Transplant. 2024 Oct 17. doi: 10.1038/s41409-024-02440.
    >> Share

  136. HUANG XB, Yang X, Li CL, Zhang R, et al
    Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.
    Bone Marrow Transplant. 2024 Oct 14. doi: 10.1038/s41409-024-02433.
    >> Share

  137. YALCIN K, Uygun V, Ozturk Hismi B, Celen S, et al
    Hematopoietic stem cell transplantation in children with mucopolysaccharidosis IVA: single center experience.
    Bone Marrow Transplant. 2024 Oct 14. doi: 10.1038/s41409-024-02439.
    >> Share

  138. BEKADJA MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, et al
    Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2024 Oct 7. doi: 10.1038/s41409-024-02431.
    >> Share

  139. SCHNEIDEWIND L, Neumann T, Peters N, Kranz J, et al
    Correction: Significance of men's health in long-term survivors of allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Oct 4. doi: 10.1038/s41409-024-02415.
    >> Share

  140. BERTUGLIA G, Garibaldi B, Casson A, Sarina B, et al
    Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor.
    Bone Marrow Transplant. 2024 Oct 4. doi: 10.1038/s41409-024-02432.
    >> Share

    September 2024
  141. SHIMOMURA Y, Kitamura T, Sugita J, Terao T, et al
    Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapy.
    Bone Marrow Transplant. 2024 Sep 30. doi: 10.1038/s41409-024-02424.
    >> Share

  142. BAYOUMY M, Almasari A, Orabe A, Shihata N, et al
    Impact of JACIE accreditation on safety of patient care: healthcare providers perspective from a tertiary care stem cell transplant center in Saudi Arabia.
    Bone Marrow Transplant. 2024 Sep 28. doi: 10.1038/s41409-024-02387.
    >> Share

  143. XU LP, Lu PH, Wu DP, Huang H, et al
    Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.
    Bone Marrow Transplant. 2024 Sep 25. doi: 10.1038/s41409-024-02419.
    >> Share

  144. PEDERSEN LL, Gerbek T, Sorum ME, Muhic E, et al
    Dietary intake and risk of metabolic syndrome in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Sep 18. doi: 10.1038/s41409-024-02412.
    >> Share

  145. ALDEBERT C, Fahd M, Galimard JE, Ghemlas IA, et al
    Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT.
    Bone Marrow Transplant. 2024 Sep 18. doi: 10.1038/s41409-024-02416.
    >> Share

  146. DUARTE GC, Ladvanszky L, Atkinson G, Burns M, et al
    Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations.
    Bone Marrow Transplant. 2024 Sep 16. doi: 10.1038/s41409-024-02409.
    >> Share

  147. URIA-OFICIALDEGUI ML, Quintero V, Benitez-Carabante MI, Bueno D, et al
    Accurate donor and recipient selection and a short time to transplant offer excellent outcomes in upfront hematopoietic stem cell transplantation from matched unrelated donors for pediatric severe aplastic anemia and refractory cytopenia of childhood.
    Bone Marrow Transplant. 2024 Sep 3. doi: 10.1038/s41409-024-02406.
    >> Share

    August 2024
  148. ZHANG H, Guo W, Wang J, Lu N, et al
    Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Aug 27. doi: 10.1038/s41409-024-02402.
    >> Share

  149. SILFVERBERG T, Zjukovskaja C, Noui Y, Carlson K, et al
    BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis.
    Bone Marrow Transplant. 2024 Aug 26. doi: 10.1038/s41409-024-02397.
    >> Share

  150. XIE Y, Kazakova V, Weeks LD, Gerber JM, et al
    Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Aug 25. doi: 10.1038/s41409-024-02403.
    >> Share

  151. ASENSI CANTO P, Gomez-Segui I, Montoro J, Villalba Montaner M, et al
    Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
    Bone Marrow Transplant. 2024 Aug 24. doi: 10.1038/s41409-024-02391.
    >> Share

  152. STEWART C, Owen C, Shafey M, Perry S, et al
    Reappraisal of autologous stem cell transplantation for transformed indolent lymphoma in the bendamustine era.
    Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02399.
    >> Share

  153. NAGLER A, Labopin M, Swoboda R, Blaise D, et al
    Young (<35 years) haploidentical versus old (>/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on
    Bone Marrow Transplant. 2024 Aug 18. doi: 10.1038/s41409-024-02400.
    >> Share

  154. JANSCAK M, Stelmes A, van den Berg J, Heim D, et al
    Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 13. doi: 10.1038/s41409-024-02395.
    >> Share

  155. BEER SA, Mohle R, Tabatabai G, Merle DA, et al
    Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02382.
    >> Share

  156. DEN HARTOG E, Lindemans CA, Fiocco M, Tissing WJE, et al
    Physical performance before and after hematopoietic stem cell transplantation in pediatric patients: a potential role for prehabilitation.
    Bone Marrow Transplant. 2024 Aug 8. doi: 10.1038/s41409-024-02390.
    >> Share

  157. AL HAMED R, Labopin M, Wu D, Gedde-Dahl T, et al
    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.
    Bone Marrow Transplant. 2024 Aug 2. doi: 10.1038/s41409-024-02373.
    >> Share

  158. LIU L, Han B, Zhang Y, Lei M, et al
    First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study.
    Bone Marrow Transplant. 2024 Aug 1. doi: 10.1038/s41409-024-02377.
    >> Share

    July 2024
  159. AVIGAN ZM, Arinsburg S, Pan D, Mark T, et al
    Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Bone Marrow Transplant. 2024 Jul 31. doi: 10.1038/s41409-024-02385.
    >> Share

  160. VADAKKEL G, Eng S, Proli A, Ponce DM, et al
    Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era.
    Bone Marrow Transplant. 2024 Jul 31. doi: 10.1038/s41409-024-02370.
    >> Share

  161. HUSSEIN-AGHA R, Kannengiesser C, Lainey E, Marcais A, et al
    Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC.
    Bone Marrow Transplant. 2024 Jul 30. doi: 10.1038/s41409-024-02381.
    >> Share

  162. WANG L, Gao W, Wang L, Jiang J, et al
    Impact of graft CD34+ cell counts on hematological recovery in patients receiving post-transplant cyclophosphamide prophylaxis.
    Bone Marrow Transplant. 2024 Jul 27. doi: 10.1038/s41409-024-02371.
    >> Share

  163. WANG J, Luo Y, Jia C, Yang J, et al
    Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center.
    Bone Marrow Transplant. 2024 Jul 23. doi: 10.1038/s41409-024-02368.
    >> Share

  164. ESTEVE M, Albert E, Gimenez E, Colomer E, et al
    Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis.
    Bone Marrow Transplant. 2024 Jul 20. doi: 10.1038/s41409-024-02376.
    >> Share

  165. TSAKIRIS DA, Gavriilaki E, Chanou I, Meyer SC, et al
    Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems.
    Bone Marrow Transplant. 2024 Jul 14. doi: 10.1038/s41409-024-02362.
    >> Share

  166. CHOI EJ, Han JH, Park H, Park HS, et al
    Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome.
    Bone Marrow Transplant. 2024 Jul 8. doi: 10.1038/s41409-024-02364.
    >> Share

    June 2024
  167. YU Y, Chen W, Fu H, Shi J, et al
    Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 27. doi: 10.1038/s41409-024-02332.
    >> Share

  168. SANZ MA, Montoro J, Balaguer-Rosello A, Chorao P, et al
    Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
    Bone Marrow Transplant. 2024 Jun 25. doi: 10.1038/s41409-024-02319.
    >> Share

  169. MARRERO-CEPEDA C, Caballero-Velazquez T, Garcia-Canale S, Martin-Dominguez F, et al
    Monocytosis as prognostic factor for chronic graft versus host disease.
    Bone Marrow Transplant. 2024 Jun 22. doi: 10.1038/s41409-024-02333.
    >> Share

  170. KELKAR AH, Kerssens C, Groblewski N, Clancy D, et al
    Human-in-the-loop avatar chatbot shows promise in supporting hematopoietic stem cell transplantation patients.
    Bone Marrow Transplant. 2024 Jun 20. doi: 10.1038/s41409-024-02334.
    >> Share

  171. ZHU J, Xu M, Ye Y, Ru Y, et al
    Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study.
    Bone Marrow Transplant. 2024 Jun 19. doi: 10.1038/s41409-024-02335.
    >> Share

  172. SCHOEMANS H, Burns LJ, Liptrott SJ, Murray J, et al
    Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party.
    Bone Marrow Transplant. 2024 Jun 18. doi: 10.1038/s41409-024-02290.
    >> Share

  173. BOULKROUN H, Lacotte E, Angoso M, Dalle JH, et al
    Late stenosis of the small intestine and colon, an atypical feature of chronic graft-versus-host disease. National retrospective study in French pediatric allograft centers.
    Bone Marrow Transplant. 2024 Jun 17. doi: 10.1038/s41409-024-02330.
    >> Share

  174. STEINER N, Massoud R, Klyuchnikov E, Gagelmann N, et al
    Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 14. doi: 10.1038/s41409-024-02328.
    >> Share

  175. AVENOSO D, Lionel S, Maraj A
    Second allogeneic haematopoietic stem cell transplant conditioned with treosulfan and fludarabine is associated with encouraging overall survival and transplant related mortality in late relapse of myeloid malignancies.
    Bone Marrow Transplant. 2024 Jun 13. doi: 10.1038/s41409-024-02329.
    >> Share

  176. ORCHARD K, Langford J, Guy M, Lewis G, et al
    Efficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Jun 12. doi: 10.1038/s41409-024-02317.
    >> Share

  177. MARTINEZ-MUNOZ ME, Payares-Herrera C, Lipperheide I, Malo de Molina R, et al
    Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Bone Marrow Transplant. 2024;59:777-784.
    >> Share

    May 2024
  178. SINGH RB, Cho W, Liu C, Naderi A, et al
    Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 May 31. doi: 10.1038/s41409-024-02321.
    >> Share

  179. FERNANDEZ-SOJO J, Azqueta C, Valdivia E, Martorell L, et al
    Correction: Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?
    Bone Marrow Transplant. 2024 May 28. doi: 10.1038/s41409-024-02318.
    >> Share

  180. TERAO T, Matsuoka KI, Fuji S, Kawamura S, et al
    Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era.
    Bone Marrow Transplant. 2024 May 25. doi: 10.1038/s41409-024-02313.
    >> Share

  181. XHAARD A, Floch A, Ruggiu M, Robin M, et al
    Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens.
    Bone Marrow Transplant. 2024 May 25. doi: 10.1038/s41409-024-02316.
    >> Share

  182. ROBIN M, Nibourel O, Tournaire M, Michonneau D, et al
    Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.
    Bone Marrow Transplant. 2024 May 23. doi: 10.1038/s41409-024-02314.
    >> Share

  183. HU X, Wang Z, Qin Y, Xu J, et al
    Allogeneic haematopoietic stem cell transplantation might overcome the poor prognosis of adolescents and adult patients with T-lineage acute lymphoblastic leukaemia and CDKN2 deletion.
    Bone Marrow Transplant. 2024 May 20. doi: 10.1038/s41409-024-02306.
    >> Share

  184. PARK B, Pires K, Jian CY, Sano L, et al
    A library of TikToks to engage diverse populations to hematopoietic stem cell donation.
    Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02294.
    >> Share

  185. MORA E, Montoro J, Balaguer A, Rovira M, et al
    Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298.
    >> Share

  186. ROBIN M, Iacobelli S, Koster L, Passweg J, et al
    Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 May 13. doi: 10.1038/s41409-024-02293.
    >> Share

  187. PEREZ A, Gomez D, Montoro J, Chorao P, et al
    Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease.
    Bone Marrow Transplant. 2024 May 10. doi: 10.1038/s41409-024-02304.
    >> Share

  188. SINANIDIS I, Hochman MJ, Tsai HL, Randall MP, et al
    Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity conditioning allogeneic bone marrow transplantation with post-transplantation cyclophosphamide.
    Bone Marrow Transplant. 2024 May 7. doi: 10.1038/s41409-024-02299.
    >> Share

  189. BERNING P, Kolloch L, Reicherts C, Call S, et al
    Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.
    Bone Marrow Transplant. 2024 May 3. doi: 10.1038/s41409-024-02295.
    >> Share

  190. AYUK F, Wagner-Drouet EM, Wolff D, von Huenerbein N, et al
    Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.
    Bone Marrow Transplant. 2024 May 2. doi: 10.1038/s41409-024-02289.
    >> Share

    April 2024
  191. DAVIDOV Y, Shem-Tov N, Yerushalmi R, Hod T, et al
    Liver stiffness measurements predict Sinusoidal Obstructive Syndrome after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Apr 24. doi: 10.1038/s41409-024-02288.
    >> Share

  192. XU W, Chen W, Guo J, Zhao L, et al
    Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis.
    Bone Marrow Transplant. 2024 Apr 24. doi: 10.1038/s41409-024-02292.
    >> Share

  193. ALSUHEBANY N, Alshehri B, Aldairem A, Aleissa MM, et al
    Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage.
    Bone Marrow Transplant. 2024 Apr 16. doi: 10.1038/s41409-024-02273.
    >> Share

  194. NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
    Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplanta
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
    >> Share

  195. SHEN Y, Liu M, Shen D, Chu M, et al
    Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.
    >> Share

  196. TAHMAZ V, Menghesha L, Stern ME, Holtick U, et al
    Insulin eye drops for severe refractory chronic ocular graft-versus-host disease.
    Bone Marrow Transplant. 2024 Apr 10. doi: 10.1038/s41409-024-02272.
    >> Share

  197. WANG L, Xu G, Wang L, Jiang J, et al
    Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning.
    Bone Marrow Transplant. 2024 Apr 10. doi: 10.1038/s41409-024-02277.
    >> Share

  198. FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
    Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.
    Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
    >> Share

  199. ZHANG X, Zhao X, Chen S, Hao M, et al
    Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients.
    Bone Marrow Transplant. 2024 Apr 5. doi: 10.1038/s41409-024-02266.
    >> Share

  200. MA R, Zhu DP, Zhang XH, Xu LP, et al
    Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience.
    Bone Marrow Transplant. 2024 Apr 2. doi: 10.1038/s41409-024-02276.
    >> Share

    March 2024
  201. KOO RM, Wong E, Davis JE, Perera T, et al
    A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.
    Bone Marrow Transplant. 2024 Mar 27. doi: 10.1038/s41409-023-02195.
    >> Share

  202. ESTRAN S, Loschi M, Benachour S, Soldati A, et al
    Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial.
    Bone Marrow Transplant. 2024 Mar 20. doi: 10.1038/s41409-024-02271.
    >> Share

  203. GUIEZE R, Eikema DJ, Koster L, Schetelig J, et al
    Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Mar 19. doi: 10.1038/s41409-024-02256.
    >> Share

  204. YADAV H, Herasevich S, Zhang Z, White BA, et al
    Pulmonary function as a continuum of risk: critical care utilization and survival after allogeneic hematopoietic stem cell transplantation - a multicenter cohort study.
    Bone Marrow Transplant. 2024 Mar 16. doi: 10.1038/s41409-024-02265.
    >> Share

  205. ROBIN M, Iacobelli S, Koster L, Passweg J, et al
    Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Mar 15. doi: 10.1038/s41409-024-02269.
    >> Share

  206. FURST S, Bernit E, Legrand F, Granata A, et al
    Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease.
    Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02257.
    >> Share

  207. SAUER S, Engelhardt M, Trautmann-Grill K, Kimmich C, et al
    Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany.
    Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02208.
    >> Share

  208. MORRIS SL, Thomas BR, Palanicawandar R, Whittaker S, et al
    Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
    Bone Marrow Transplant. 2024 Mar 12. doi: 10.1038/s41409-024-02236.
    >> Share

  209. FRAEBEL J, Park S, Shah R, Prieto-Granada C, et al
    GVHD like skin eruption post-autologous stem cell transplantation.
    Bone Marrow Transplant. 2024 Mar 11. doi: 10.1038/s41409-024-02259.
    >> Share

  210. FAZIO F, Passucci M, Micozzi J, Di Landro F, et al
    Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
    Bone Marrow Transplant. 2024 Mar 9. doi: 10.1038/s41409-024-02260.
    >> Share

  211. DACHY G, Vankeerbergen M, Vanlangendonck N, Straetmans N, et al
    Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Mar 8. doi: 10.1038/s41409-024-02242.
    >> Share

  212. CHU SC, Hsieh CJ, Li CC, Yang SH, et al
    Long-term follow-up of cancer and catastrophic diseases in hematopoietic stem cell donors: a comprehensive matched cohort study.
    Bone Marrow Transplant. 2024 Mar 7. doi: 10.1038/s41409-024-02204.
    >> Share

  213. SHANG Q, Bai L, Cheng Y, Suo P, et al
    Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation in children with FLT3-ITD mutated acute myeloid leukaemia.
    Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02214.
    >> Share

  214. PARK S, Bang SY, Kwag D, Lee JH, et al
    Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.
    Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255.
    >> Share

    February 2024
  215. YANG YM, Guo SJ, Xiao R, Yu XJ, et al
    Prevalence of osteoporosis among patients after stem cell transplantation: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2024 Feb 29. doi: 10.1038/s41409-024-02243.
    >> Share

  216. BACCELLI F, Gottardi F, Muratore E, Leardini D, et al
    Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02252.
    >> Share

  217. FINAZZI MC, Weber A, Pavoni C, Grassi A, et al
    Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02247.
    >> Share

  218. MURRAY A, Linn SM, Yu B, Novitzky-Basso I, et al
    Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease.
    Bone Marrow Transplant. 2024 Feb 24. doi: 10.1038/s41409-024-02249.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016